Interactive Features

Quiz

Efficacy of Pirtobrutinib for Heavily-Pretreated MCL

10/30/2023

Findings from the BRUIN trial indicated that BTK inhibitor pirtobrutinib demonstrated durable and encouraging efficacy and safety outcomes among patients with heavily pretreated MCL after covalent BTK inhibitor treatment, with patients...

Findings from the BRUIN trial...

10/30/2023

Oncology

Quiz

Utilizing CAR-HEMATOTOX Score to Predict Treatment Outcomes for R/R MCL

10/20/2023

True or False: In a study assessing the prognostic value of CAR-HEMATOTOX (HT) scores in predicting outcomes among patients with R/R MCL, low baseline scores of 0 to 1 at the time of lymphodepletion before CD19-directed CAR T-cell therapy...

True or False: In a study...

10/20/2023

Oncology

Quiz

Venetoclax, Lenalidomide, and Rituximab Triplet Combination for MCL

10/18/2023

True or False: Findings from a single-arm study on the addition of venetoclax to lenalidomide and rituximab treatment for patients with previously untreated mantle cell lymphoma indicated that patients treated with this triplet combination...

True or False: Findings from a...

10/18/2023

Oncology

Quiz

R-CHOP Plus R-BAC Induction Therapy for Mantle Cell Lymphoma

10/13/2023

True or False: According to a retrospective analysis, the combination of R-CHOP and R-BAC as induction therapy was ineffective in treating transplant-eligible patients with mantle cell lymphoma.

True or False: According to a...

10/13/2023

Oncology

Quiz

Novel Therapeutic Target FGFR1 for Patients With MCL

10/10/2023

True or False: Findings from a study aiming to identify a regulator that directly contributes to the clinical outcomes of mantle cell lymphoma (MCL) indicated that fibroblast growth factor receptor-1 (FGFR1) overexpression in preclinical...

True or False: Findings from a...

10/10/2023

Oncology

Quiz

Significance of DTI for MCL Treatment Outcomes

09/25/2023

True or False: According to findings from a pooled analysis of 3 datasets assessing the potential significance of diagnosis to treatment interval (DTI) for the prognosis of mantle cell lymphoma, patients with shorter DTI were noted to have...

True or False: According to...

09/25/2023

Oncology

Quiz

Pirtobrutinib for High-Risk Subtypes of Mantle Cell Lymphoma

09/19/2023

True or False: Results of the BRUIN trial indicated that after receiving pirtobrutinib, patients with MCL with classical histology had more efficacious outcomes than patients with MCL with blastoid or pleomorphic variants.

True or False: Results of the...

09/19/2023

Oncology

Quiz

Lenalidomide, Rituximab, and Venetoclax Among Patients With Untreated MCL

08/22/2023

True or False: The combination of lenalidomide, rituximab, and venetoclax induced high rates of clinical and molecular responses and demonstrated promising efficacy and safety outcomes among patients with untreated mantle cell lymphoma,...

True or False: The combination...

08/22/2023

Oncology

Quiz

SNPs as Predictive Biomarkers for Lenalidomide Efficacy for MCL

08/14/2023

True or False: In a study assessing the predictive value of single nucleotide polymorphisms (SNPs) among patients with mantle cell lymphoma (MCL), researchers found that specific SNPs represented candidate predictive biomarkers for...

True or False: In a study...

08/14/2023

Oncology

Quiz

Ofatumumab Plus Bendamustine Combination Therapy for MCL

10/18/2022

True or False: Ofatumumab plus bendamustine is an effective and well-tolerated combination therapy for the first-line treatment of older patients with mantle cell lymphoma, according to a phase 2 study.

True or False: Ofatumumab plus...

10/18/2022

Oncology

Recent News

News

Osimertinib Lacks Activity in Neoadjuvant Setting for Early-Stage Non-Small Cell Lung Cancer With EGFR Mutation

08/08/2024

Stephanie Holland ;

Results from a phase 2 study demonstrated that neoadjuvant osimertinib did not improve the major pathological response rate among patients with early-stage non-small cell lung cancer harboring an EGFR mutation.

Results from a phase 2 study...

08/08/2024

Oncology

FDA Approval

FDA Approves Denileukin Diftitox for Patients With R/R Cutaneous T-Cell Lymphoma

08/08/2024

Amber Denham ;

The US Food and Drug Administration approved novel immunotherapy denileukin diftitox-cxdl for the treatment of patients with relapsed/refractory cutaneous T-cell lymphoma after at least 1 prior systemic therapy.

The US Food and Drug...

08/08/2024

Oncology

News

Tailored Dose-Dense Chemotherapy Improved Survival Outcomes Among Patients With High-Risk Early Breast Cancer

08/07/2024

Stephanie Holland ;

According to results from the phase 3 PANTHER trial, tailored and dose-dense chemotherapy in the adjuvant setting improved survival outcomes compared to standard chemotherapy among patients with high-risk early breast cancer.

According to results from the...

08/07/2024

Oncology

News

Frontline Treatment Management for Patients With FL Reduces Risk of High-Grade Transformation to DLBCL

08/07/2024

Amber Denham ;

A recent study demonstrated that frontline treatment management reduced the risk of high-grade transformation to diffuse large B-cell lymphoma among patients with follicular lymphoma, but not among patients with marginal zone lymphoma.

A recent study demonstrated that...

08/07/2024

Oncology

News

Optimal Sotorasib Dose for Patients With KRAS G12C-Mutated Advanced Non-Small Cell Lung Cancer

08/07/2024

Stephanie Holland ;

Results from a phase 2 study found that 960 mg of sotorasib is preferable to 240 mg among patients with previously treated KRAS G12C-mutated locally advanced or metastatic non-small cell lung cancer.

Results from a phase 2 study...

08/07/2024

Oncology

FDA Approval

FDA Approves Vorasidenib for Patients With IDH1/IDH2-Mutated Grade 2 Astrocytoma or Oligodendroglioma

08/06/2024

Stephanie Holland ;

Based on results from the INDIGO trial, the FDA has approved vorasidenib for adult and pediatric patients 12 years and older with grade 2 astrocytoma or oligodendroglioma with a susceptible IDH1 or IDH2 mutation following surgery.

Based on results from the INDIGO...

08/06/2024

Oncology

FDA Approval

FDA Approves Afamitresgene Autoleucel for Certain Unresectable or Metastatic Synovial Sarcoma

08/02/2024

Allison Casey ;

On August 2, 2024, the US Food and Drug Administration (FDA) granted accelerated approval to afamitresgene autoleucel for the treatment of adult patients with certain unresectable or metastatic synovial sarcomas who had received prior...

On August 2, 2024, the US Food...

08/02/2024

Oncology

FDA Approval

FDA Approves Dostarlimab Plus Chemotherapy for Patients With Primary Advanced or Recurrent Endometrial Cancer

08/01/2024

Allison Casey ;

The FDA approved dostarlimab plus carboplatin and paclitaxel, followed by single-agent dostarlimab for patients with primary advanced or recurrent endometrial cancer.

The FDA approved dostarlimab...

08/01/2024

Oncology

News

Iadademstat and Azacitidine Combination Therapy Demonstrates Manageable Safety, Promising Efficacy for Patients With Newly Diagnosed AML

08/01/2024

Amber Denham ;

The first-line combination of iadademstat and azacitidine demonstrates a manageable safety profile and promising results among patients with acute myeloid leukemia, according to phase 2 results from the ALICE trial.

The first-line combination of...

08/01/2024

Oncology

News

Effect of Food on Selumetinib Dosing for Adolescent Patients With Neurofibromatosis Type 1 With Plexiform Neurofibromas

08/01/2024

Allison Casey ;

In the phase 1 trial, the addition of a low-fat meal with doses of selumetinib did not significantly impact selumetinib exposure or gastrointestinal toxicities among adolescent patients with neurofibromatosis type 1 with plexiform...

In the phase 1 trial, the...

08/01/2024

Oncology